Peptides DB
Research-centric peptide and protocol reference hub

Erythropoietin (EPO) record · updated 18h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 38 studiesJump to the evidenceCompare
What is Erythropoietin (EPO) used for?

Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys in response to hypoxia. Its main function is to stimulate the production of red blood cells (erythropoiesis) in the bone marrow by binding to erythropoietin receptors (EPOR) on erythroid progenitor cells. This interaction activates various intracellular signaling pathways, including the JAK2/STAT5 pathway, which promotes cell survival, proliferation, and differentiation of erythroid progenitors.

How it works: EPOR agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Erythropoietin (EPO) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 219 registered trials. It describes the research record, not a recommendation.

Identity
NameErythropoietin (EPO)
Chain length—
Molecular weight848 Da
FormulaC42H73NO16
Structure typeNot established
ClassHealing
Research levelWell Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 92043599. No verified residue count for this compound.

Pharmacology
MechanismEPOR agonist
RouteSubcutaneous injection
Half-life~4–13 hours
Time to peak~5 hours
Duration~24 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 7, 2026. How this works →
Research stats
Total studies38
Human / animal / cellular21 / 5 / 3
Highest trial phasePreclinical
Years covered2024–2026
Latest study11d ago
Publication history
20242026
Research funding
1,660 NIH projects · $24.8M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports2
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

38 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Blood Free Carnitine Level is an Independent Determinant of Erythrocyte Membrane Homogeneity and Osmotic Resistance in Maintenance Hemodialysis Patients
FindingHigher FC levels were associated with increased OFT slope a (β=0.6090, P=0.036).
Human2026Full text read0.80
Genetic mimicry of haematopoietic growth factor signalling: efficacy–safety trade-offs for cytopenias by drug-target Mendelian randomisation
FindingOR 0.65, 95% CI 0.49–0.86, P=0.0026 for lower thrombocytopenia risk with higher MPL expression.
Human2026Full text read0.80
In vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cells
Finding>70% HbF-positive erythroid cells in treated mice
Animal2026Full text read0.70
Early and late erythropoietin do not alter oxygen induced retinopathy severity in a rat model of anemia
FindingNot reported in abstract.
Animal2026Full text read0.70
Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.
TakeawayNot reported in abstract.
—2026Title only0.10
Prevalence and risk of cardiovascular events among people living with HIV: a meta-analysis.
FindingPooled prevalence of cardiovascular events was 6% (95% CI: 0.05-0.07).
review2026Full text read0.90
Real-world effectiveness of central dialysis fluid delivery system (CDDS) in maintenance hemodialysis: a retrospective multicenter study.
Findingβ = 3.50 g/L hemoglobin compared to SPDDS, p < 0.05
Human2026Full text read0.80
Impaired fasting glucose is comparable to diabetes mellitus in predicting mortality and cardiovascular events in patients undergoing peritoneal dialysis: the role of β-cell function and insulin resistance.
FindingIFG independently predicted all-cause mortality (HR, 2.48; 95% CI, 1.16-5.32; p=0.02).
Human2026Full text read0.80
The relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and tubular atrophy/interstitial fibrosis in patients with IgA nephropathy.
FindingNHHR was positively correlated with T lesions (r = 0.229, p < 0.001).
Human2026Full text read0.90
Association Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study.
FindingWeek 1 estimated glomerular filtration rate: 53.3 ± 16.1 vs control 41.9 ± 17.9 mL/min/1.73 m²; P = 0.001
Human2026Full text read0.80
Analytical validation of an ultrasensitive multiplexed immunoassay for blood-based biomarkers GFAP, NF-L and tau
FindingIntra-plate %CV averaged less than 10%.
In vitro2026Full text read0.70
Plasma erythropoietin responses across repeated exposure to normobaric hypoxia in healthy older adults
FindingPlasma EPO increased by an estimated mean of 6.33 mIU/mL from baseline to 3 h post-exposure.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Erythropoietin (EPO) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Erythropoietin (EPO) is discussed should be drawn from it.

Articles mentioning Erythropoietin (EPO)